Literature DB >> 19596610

T cell receptor signaling induced by an analog peptide of type II collagen requires activation of Syk.

Bo Tang1, Jing Zhou, Jeoung-Eun Park, David Cullins, Ae-Kyung Yi, Andrew H Kang, John M Stuart, Linda K Myers.   

Abstract

We have previously described an analog peptide of type II collagen (CII) that can suppress collagen-induced arthritis (CIA). This analog peptide represents CII(245-270), the immunodominant epitope of CII, but with substitutions at 260, 261, and 263 - CII(245-270) (A(260), B(261), and N(263)) (A9). To elucidate the mechanisms responsible for suppression, we used mice transgenic for a collagen-specific T cell receptor (TCR). When we found that APCs pulsed with A9 failed to induce T cell phosphorylation of TCR-zeta and ZAP-70, we explored alternative signaling pathways. We determined that A9 instead induced phosphorylation of spleen tyrosine kinase (Syk). The importance of Syk was confirmed by the use of chemical Syk inhibitors, which blocked both cytokine secretion and activation of GATA-3 mediated by peptide A9. In summary, T cells use an alternative pathway in response to A9 that involves Syk. This novel T cell pathway may represent an important means for altering T cell phenotypes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596610      PMCID: PMC2756788          DOI: 10.1016/j.clim.2009.06.006

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  40 in total

1.  Detection of early changes in autoimmune T cell phenotype and function following intravenous administration of type II collagen in a TCR-transgenic model.

Authors:  David D Brand; Linda K Myers; Karen B Whittington; Kary A Latham; John M Stuart; Andrew H Kang; Edward F Rosloniec
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

2.  The role of IL-4 in regulation of murine collagen-induced arthritis.

Authors:  L K Myers; B Tang; J M Stuart; A H Kang
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

3.  Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4.

Authors:  S H Kim; S Kim; C H Evans; S C Ghivizzani; T Oligino; P D Robbins
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

4.  Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types.

Authors:  L Dumoutier; C Leemans; D Lejeune; S V Kotenko; J C Renauld
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

5.  Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium.

Authors:  S Watanabe; T Imagawa; G P Boivin; G Gao; J M Wilson; R Hirsch
Journal:  Mol Ther       Date:  2000-08       Impact factor: 11.454

6.  Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.

Authors:  L Kappos; G Comi; H Panitch; J Oger; J Antel; P Conlon; L Steinman
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

7.  Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand.

Authors:  H J Kim; J P Antel; P Duquette; D G Alleva; P J Conlon; A Bar-Or
Journal:  Clin Immunol       Date:  2002-08       Impact factor: 3.969

8.  Regulation of Akt-dependent cell survival by Syk and Rac.

Authors:  Kun Jiang; Bin Zhong; Connie Ritchey; Danielle L Gilvary; Elizabeth Hong-Geller; Sheng Wei; Julie Y Djeu
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

Review 9.  Transcriptional regulation of IL-2 in health and autoimmunity.

Authors:  José C Crispín; George C Tsokos
Journal:  Autoimmun Rev       Date:  2008-08-24       Impact factor: 9.754

10.  Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.

Authors:  L A Joosten; E Lubberts; M M Helsen; T Saxne; C J Coenen-de Roo ; D Heinegård; W B van den Berg
Journal:  Arthritis Res       Date:  1999-10-26
View more
  9 in total

1.  The role of Syk in peripheral T cells.

Authors:  Jeoung-Eun Park; Sirshendu Majumdar; David D Brand; Edward F Rosloniec; Ae-Kyung Yi; John M Stuart; Andrew H Kang; Linda K Myers
Journal:  Clin Immunol       Date:  2018-04-16       Impact factor: 3.969

2.  Characterization of the Syk-Dependent T Cell Signaling Response to an Altered Peptide.

Authors:  Jeoung-Eun Park; Jeffrey A Rotondo; David L Cullins; David D Brand; Ae-Kyung Yi; John M Stuart; Andrew H Kang; Linda K Myers
Journal:  J Immunol       Date:  2016-11-11       Impact factor: 5.422

3.  Peptide ligand structure and I-Aq binding avidity influence T cell signaling pathway utilization.

Authors:  Linda K Myers; David L Cullins; Jeoung-Eun Park; Ae-Kyung Yi; David D Brand; Edward F Rosloniec; John M Stuart; Andrew H Kang
Journal:  Clin Immunol       Date:  2015-05-14       Impact factor: 3.969

4.  T cells stimulated with an analog peptide of type II collagen require the Fc receptor γ-chain to secrete interleukin-4 and suppress autoimmune arthritis in mice.

Authors:  Linda K Myers; David L Cullins; David D Brand; Sandra Kleinau; John M Stuart; Andrew H Kang
Journal:  Arthritis Rheum       Date:  2011-09

5.  Molecular basis for T cell response induced by altered peptide ligand of type II collagen.

Authors:  Jeoung-Eun Park; David Cullins; Lillian Zalduondo; Stacey L Barnett; Ae-Kyung Yi; Sandra Kleinau; John M Stuart; Andrew H Kang; Linda K Myers
Journal:  J Biol Chem       Date:  2012-04-16       Impact factor: 5.157

6.  Design of glycopeptides used to investigate class II MHC binding and T-cell responses associated with autoimmune arthritis.

Authors:  Ida E Andersson; C David Andersson; Tsvetelina Batsalova; Balik Dzhambazov; Rikard Holmdahl; Jan Kihlberg; Anna Linusson
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

Review 7.  Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases.

Authors:  Yuya Takakubo; Yrjö T Konttinen
Journal:  Clin Dev Immunol       Date:  2011-10-27

Review 8.  Peptide-Based Vaccination Therapy for Rheumatic Diseases.

Authors:  Bin Wang; Shiju Chen; Qing Zheng; Yuan Liu; Guixiu Shi
Journal:  J Immunol Res       Date:  2020-03-18       Impact factor: 4.818

Review 9.  Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Front Immunol       Date:  2021-11-17       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.